Taysha Gene Therapies, Inc. TSHA Shares (Basic)
Shares (Basic) at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s shares (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s shares (basic)?
- Taysha Gene Therapies, Inc. (TSHA) reported shares (basic) of 366.6M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s shares (basic) changed year-over-year?
- Taysha Gene Therapies, Inc.'s shares (basic) increased by 36.1% year-over-year, from 269.3M to 366.6M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s shares (basic)?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s shares (basic) has grown at a 96.6% compound annual growth rate (CAGR), from 163.2M to 1.2B.
- What does shares (basic) mean?
- The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.